|
1
|
Jemal A, Siegel R, Ward E, et al: Cancer
statistics, 2009. CA Cancer J Clin. 59:225–249. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fukuoka M, Yano S, Giaccone G, et al:
Multi-institutional randomized phase II trial of gefitinib for
previously treated patients with advanced non-small-cell lung
cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 21:2237–2246.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kris MG, Natale RB, Herbst RS, et al:
Efficacy of gefitinib, an inhibitor of the epidermal growth factor
receptor tyrosine kinase, in symptomatic patients with non-small
cell lung cancer: a randomized trial. JAMA. 290:2149–2158. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jänne PA, Gurubhagavatula S, Yeap BY, et
al: Outcomes of patients with advanced non-small cell lung cancer
treated with gefitinib (ZD1839, ‘Iressa’) on an expanded access
study. Lung Cancer. 44:221–230. 2004. View Article : Google Scholar
|
|
5
|
Santoro A, Cavina R, Latteri F, et al:
Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of
epidermal growth factor receptor in refractory non-small-cell lung
cancer. Ann Oncol. 15:33–37. 2004. View Article : Google Scholar
|
|
6
|
Park J, Park BB, Kim JY, et al: Gefitinib
(ZD1839) monotherapy as a salvage regimen for previously treated
advanced non-small cell lung cancer. Clin Cancer Res. 10:4383–4388.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Konishi J, Yamazaki K, Kinoshita I, et al:
Analysis of the response and toxicity to gefitinib of non-small
cell lung cancer. Anticancer Res. 25:435–441. 2005.PubMed/NCBI
|
|
8
|
Simon GR, Ruckdeschel JC, Williams C, et
al: Gefitinib (ZD1839) in previously treated advanced
non-small-cell lung cancer: experience from a single institution.
Cancer Control. 10:388–395. 2003.PubMed/NCBI
|
|
9
|
Lee DH, Han JY, Lee HG, et al: Gefitinib
as a first-line therapy of advanced or metastatic adenocarcinoma of
the lung in never-smokers. Clin Cancer Res. 11:3032–3037. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lynch TJ, Bell DW, Sordella R, et al:
Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to
gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Paez JG, Jänne PA, Lee JC, et al: EGFR
mutations in lung cancer: correlation with clinical response to
gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Okamoto I, Takahashi T, Okamoto H, et al:
Single-agent gefitinib with concurrent radiotherapy for locally
advanced non-small cell lung cancer harboring mutations of the
epidermal growth factor receptor. Lung Cancer. 72:199–204. 2011.
View Article : Google Scholar
|
|
13
|
Cappuzzo F, Hirsch FR, Rossi E, et al:
Epidermal growth factor receptor gene and protein and gefitinib
sensitivity in non-small-cell lung cancer. J Natl Cancer Inst.
97:643–655. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hirsch FR, Herbst RS, Olsen C, et al:
Increased EGFR gene copy number detected by fluorescent in situ
hybridization predicts outcome in non-small-cell lung cancer
patients treated with cetuximab and chemotherapy. J Clin Oncol.
26:3351–3357. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cappuzzo F, Magrini E, Ceresoli GL, et al:
Akt phosphorylation and gefitinib efficacy in patients with
advanced non-small-cell lung cancer. J Natl Cancer Inst.
96:1133–1141. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Engelman JA, Jänne PA, Mermel C, et al:
ErbB-3 mediates phosphoinositide 3-kinase activity in
gefitinib-sensitive non-small cell lung cancer cell lines. Proc
Natl Acad Sci USA. 102:3788–3793. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mitsudomi T, Kosaka T, Endoh H, et al:
Mutations of the epidermal growth factor receptor gene predict
prolonged survival after gefitinib treatment in patients with
non-small-cell lung cancer with postoperative recurrence. J Clin
Oncol. 23:2513–2520. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Han SW, Kim TY, Hwang PG, et al:
Predictive and prognostic impact of epidermal growth factor
receptor mutation in non-small-cell lung cancer patients treated
with gefitinib. J Clin Oncol. 23:2493–2501. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hirsch FR, Varella-Garcia M, McCoy J, et
al: Southwest Oncology Group: Increased epidermal growth factor
receptor gene copy number detected by fluorescence in situ
hybridization associates with increased sensitivity to gefitinib in
patients with bronchioloalveolar carcinoma subtypes: a Southwest
Oncology Group Study. J Clin Oncol. 23:6838–6845. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tokumo M, Toyooka S, Kiura K, et al: The
relationship between epidermal growth factor receptor mutations and
clinicopathologic features in non-small cell lung cancers. Clin
Cancer Res. 11:1167–1173. 2005.PubMed/NCBI
|
|
21
|
Kim KS, Jeong JY, Kim YC, et al:
Predictors of the response to gefitinib in refractory non-small
cell lung cancer. Clin Cancer Res. 11:2244–2251. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Takano T, Ohe Y, Sakamoto H, et al:
Epidermal growth factor receptor gene mutations and increased copy
numbers predict gefitinib sensitivity in patients with recurrent
non-small-cell lung cancer. J Clin Oncol. 23:6829–6837. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Riely GJ, Pao W, Pham D, et al: Clinical
course of patients with non-small cell lung cancer and epidermal
growth factor receptor exon 19 and exon 21 mutations treated with
gefitinib or erlotinib. Clin Cancer Res. 12:839–844. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Eisenhauer EA, Therasse P, Bogaerts J, et
al: New response evaluation criteria in solid tumors: revised
RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.
View Article : Google Scholar
|
|
25
|
Trotti A, Byhardt R, Stetz J, et al:
Common toxicity criteria: version 2.0. an improved reference for
grading the acute effects of cancer treatment: impact on
radiotherapy. Int J Radiat Oncol Biol Phys. 47:13–47. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cella D, Herbst RS, Lynch TJ, et al:
Clinically meaningful improvement in symptoms and quality of life
for patients with non-small-cell lung cancer receiving gefitinib in
a randomized controlled trial. J Clin Oncol. 23:2946–2954. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yokouchi H, Yamazaki K, Kinoshita I, et
al: Clinical benefit of readministration of gefitinib for initial
gefitinib-responders with non-small cell lung cancer. BMC Cancer.
7:512007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mok TS, Wu YL, Thongprasert S, et al:
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N
Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Park K and Goto K: A review of the
benefit-risk profile of gefitinib in Asian patients with advanced
non-small-cell lung cancer. Curr Med Res Opin. 22:561–573. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Inoue A, Suzuki T, Fukuhara T, et al:
Prospective phase II study of gefitinib for chemotherapy-naive
patients with advanced non-small-cell lung cancer with epidermal
growth factor receptor gene mutations. J Clin Oncol. 24:3340–3346.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hotta K, Matsuo K, Ueoka H, et al:
Continued gefitinib treatment after disease stabilisation prolongs
survival of Japanese patients with non-small-cell lung cancer:
Okayama Lung Cancer Study Group experience. Ann Oncol.
16:1817–1823. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yang JJ, Chen HJ, Yan HH, et al: Clinical
modes of EGFR tyrosine kinase inhibitor failure and subsequent
management in advanced non-small cell lung cancer. Lung Cancer.
79:33–39. 2013. View Article : Google Scholar
|
|
33
|
Omuro AM, Kris MG, Miller VA, et al: High
incidence of disease recurrence in the brain and leptomeninges in
patients with nonsmall cell lung carcinoma after response to
gefitinib. Cancer. 103:2344–2348. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fukuhara T, Saijo Y, Sakakibara T, et al:
Successful treatment of carcinomatous meningitis with gefitinib in
a patient with lung adenocarcinoma harboring a mutated EGF receptor
gene. Tohoku J Exp Med. 214:359–363. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jackman DM, Holmes AJ, Lindeman N, et al:
Response and resistance in a non-small-cell lung cancer patient
with an epidermal growth factor receptor mutation and
leptomeningeal metastases treated with high-dose gefitinib. J Clin
Oncol. 24:4517–4520. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ma S, Xu Y, Deng Q and Yu X: Treatment of
brain metastasis from non-small cell lung cancer with whole brain
radiotherapy and Gefitinib in a Chinese population. Lung Cancer.
65:198–203. 2009. View Article : Google Scholar
|
|
37
|
Ma S, Xu Y, et al: Prophylactic Cranial
Irradiation (PCI) in Erlotinib/Gefitinib-Responders With Non-small
Cell Lung Cancer (NSCLC) (RT1001). ClinicalTrialsgov Identifier:
NCT01158170. 2010.
|
